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To analyze the molecular epidemiology of 
Mycobacterium tuberculosis strains at a hospital in Buenos 
Aires, Argentina, and mutations related to multidrug-
resistant and extensively drug-resistant tuberculosis, we 
conducted a prospective case–control study. Our ﬁ  ndings 
reinforce the value of incorporating already standardized 
molecular methods for rapidly detecting resistance.
D
uring the 1990s, an outbreak of multidrug-resistant 
(MDR) tuberculosis (TB) in HIV-positive patients 
occurred at the Muñiz Hospital in Buenos Aires, Argentina 
(1). Molecular analysis showed that a member of Haarlem2 
family of Mycobacterium tuberculosis was responsible (1).
We conducted a prospective case-control study during 
June 1, 2006–April 30, 2007, at this 300-bed public hospital, 
which reports ≈40% of new TB cases in the city (2). Our 
primary aims were to analyze the molecular epidemiology 
of M. tuberculosis strains circulating at the hospital and 
the mutations related to MDR TB and extensively drug-
resistant TB.
The Study
The strains were isolated and tested for antimicrobial 
drug susceptibility according to the proportion method 
(3) at the Muñiz Hospital Mycobacteria Laboratory. A 
proportion were tested for reserve drugs at the Health 
Protection Agency National Mycobacteria Reference 
Unit Laboratory, London, UK. DNA was extracted 
from cultures at this UK laboratory; spoligotyping was 
performed according to the manufacturer’s instructions 
(Isogen Life Science, IJsselstein, the Netherlands); and 
data were analyzed with SPOTCLUST (http://cgi2.cs.rpi.
edu/~bennek/SPOTCLUST.html).
We performed 15-locus variable number tandem 
repeat (VNTR) using a CEQ 8000 Genetic Analysis System 
(Beckman Coulter, Inc., Fullerton, CA, USA) (4). Cluster 
analysis was performed by using Bionumerics software 
(Applied Maths, St-Martens-Latem, Belgium). Strains 
lacking a unique pattern were subjected to further analysis 
with an expanded set of VNTR loci (5).
In-house macroarrays were performed on MDR TB 
strains (6) to identify mutations in the katG and the inhA 
genes. Two regions of the rpoB gene of MDR TB strains 
were sequenced with the CEQ 8000 Genetic Analysis 
System. Statistical analyses were conducted by using χ2 
and Fisher exact tests.
After we excluded duplicates, treatment follow-ups, 
and strains with susceptibility patterns other than MDR 
TB or susceptibility to all drugs tested, 881 strains were 
susceptible to all drugs tested. Patients with a minimum 
dataset (name, sex, date of birth or age, TB presentation 
[i.e., pulmonary or nonpulmonary], and at least 1 sign or 
symptom describing TB illness and treatment received) 
were enrolled: 57 of 62 hospitalized patients with MDR 
TB cultures (Table) and 100 fully susceptible unmatched 
inpatient controls, for a total of 157 patients. This 
convenience sample (Figure 1) included only admitted 
patients because of the difﬁ   culty of obtaining clinical 
information about outpatients.
The most common spoligofamilies were T1 (18%), 
Haarlem 1 (10%), 2 (16%), and 3 (11%), LAM 3 (10%), 
and LAM 9 (13%). Initial 15-loci VNTR analysis showed 
73 strains with unique patterns. Further analysis using 
7-loci VNTR was performed on those that did not have 
a unique pattern. Twenty-six isolates remained clustered 
(Figure 2).
Of the 57 MDR TB strains, 43 had a mutation in the 
katG315 locus, and 6 had a mutation in the inhA region. No 
strain had mutations in both genes. In 8 strains, resistance 
to isoniazid was not mediated by mutations in any of them.
Mutations in the rpoB region were detected by 
sequencing. The most frequent mutation was the S531L. 
Mutations at >1 site were rare. In 3 cases, we found 2 point 
mutations in the same codon. Only 1 MDR TB strain had no 
mutation in the rpoB segment sequenced; it also had a katG 
and inhA wild type. Complete susceptibility proﬁ  le for all 
57 MDR TB strains is available in the online Appendix 
Table (www.cdc.gov/EID/content/17/3/528-appT.htm).
In addition, we detected 5 extensively drug-resistant 
TB strains. None were clustered by 22-loci VNTR typing.
Conclusions
Spoligotyping identiﬁ  ed predominance of the Haarlem 
family among the MDR TB cases (family responsible for 
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the 1990s [1] outbreak) as well as the LAM and T families. 
A similar strain family distribution was reported for the 
French Departments of the Americas (7) and Turkey (8). 
The Beijing family was seldom encountered in these areas, 
which is in line with recent observations in 7 countries in 
South America, including Argentina (9).
The MDR TB Haarlem2 strain appears to be more 
successful than other circulating MDR TB strains and than 
its susceptible counterpart (of 25 Haarlem2 strains, 20 were 
MDR TB). This phenomenon could be associated with a 
bias in the sample resulting from the specialized nature of 
the hospital or it could be that the MDR TB version has 
become predominant in the population because of the low 
ﬁ  tness cost of its 2 mutations, katG315 and S531L (10,11). 
In addition, the presence of clusters suggests that even 
though new technologies have reduced the time taken to 
diagnose drug resistance, more rapid initial diagnosis of 
MDR TB to reduce transmission still is needed (12).
All except 1 of the rpoB mutations in the MDR TB 
strains were at nt positions 1303–1375. This ﬁ  nding 
reinforces the value of incorporating already standardized 
molecular methods for rapidly detecting resistance. Cost 
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Table. Demographic information for 157 patients in a study of the molecular epidemiology of TB, Buenos Aires, Argentina, June 1,
2006–April 30, 2007* 
Demographic characteristic 
Patients with MDR TB, 
n = 57, no. (%)† 
Patients with non–MDR TB, 
n = 100, no. (%)‡  p value, OR (95% CI)§ 
Sex
  M  35 (61)  70 (70)  0.271, 1.4667 (0.7404–2.9055) 
  F  22 (39)  30 (30) 
Location
  Buenos Aires area  46 (81)  95 (95)  0.004, 4.5435 (1.491–13.845) 
  Other  11 (19)  5 (5) 
Country of birth 
  Argentina  43 (75)  66 (66)  0.2176, 0.632 (0.3041–1.3133) 
  Bolivia  6 (11)  20 (20) 
  Peru  7 (12)  8 (8) 
 Paraguay  0 3  (3) 
  Uruguay  1 (2)  1 (1) 
 Chile  0 1  (1) 
  Missing data  0 1 (1) 
Education
  Illiterate or some primary  16 (28)  32 (32)  0.2059, 0.5185 (0.1860–1.4456) 
  Some secondary or tertiary  7 (12)  27 (27) 
  Missing data  34 (59)  41 (41) 
Occupation
 Unemployed  7  (12) 
  Construction and manual worker  20 (35) 
  Factory worker  4 (7)  14 (14) 
  Health care worker  1 (2)  1 (1) 
  Education, i.e., student and teacher  2 (4)  4 (4) 
  Housewife  6 (11)  5 (5) 
  Missing data  17 (30)  23 (23) 
HIV infection 
  Positive  25 (44)  27 (27)  0.04, 0.4737 (0.2308–0.9722) 
  Negative  25 (44)  57 (57) 
  Missing data  7 (12)  16 (16) 
Nature of TB contact 
  Close (i.e., household, family, co-worker)  10 (18)  32 (32) 
  Institution (i.e., hospital, prison)  2 (4)  3 (3) 
  Casual (e.g., acquaintance)  5 (9)  3 (3) 
  Missing data  40 (70)  62 (62) 
TB presentation 
  Pulmonary  36 (63)  61 (61)  0.7184, 1.1553 (0.5323–2.5073) 
  Nonpulmonary  15 (26)  22 (22) 
  Missing data  6 (11)  17 (17) 
*TB, tuberculosis; MDR, multidrug resistant; OR, odds ratio; CI, confidence interval; IQR, interquartile range. 
†Median age, y (IQR) for patients with MDR TB: 34 (27–40). 
‡Median age, y (IQR) for patients with non-MDR TB: 28.5 (23.0–37.0). 
§Ȥ
2 test. is the main reason they are currently not available, but 
the macroarrays used in this project are inexpensive and 
have the additional advantage of analyzing katG and inhA 
mutations independently.
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Figure 1. Multistage cluster sampling method for a study of the 
molecular epidemiology of Mycobacterium tuberculosis, Buenos 
Aires, Argentina, June 1, 2006–April 30, 2007. *Complete, having 
all but one of the following data: name, gender, date of birth or age, 
tuberculosis (TB) presentation, >1 sign or symptom describing the 
presentation and treatment received. †Unmatched controls. MDR, 
multidrug-resistant.
Figure 2. Final cluster results in a study of the molecular 
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